ZA9510924B - Soluble 2-chloro-2'-deoxyadenosine formulations - Google Patents

Soluble 2-chloro-2'-deoxyadenosine formulations

Info

Publication number
ZA9510924B
ZA9510924B ZA9510924A ZA9510924A ZA9510924B ZA 9510924 B ZA9510924 B ZA 9510924B ZA 9510924 A ZA9510924 A ZA 9510924A ZA 9510924 A ZA9510924 A ZA 9510924A ZA 9510924 B ZA9510924 B ZA 9510924B
Authority
ZA
South Africa
Prior art keywords
formulations
deoxyadenosine
chloro
soluble
cda
Prior art date
Application number
ZA9510924A
Other languages
English (en)
Inventor
Michael Bornstein
Rosemary Rozman
Kevin Francis Long
George Kaon Wong
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of ZA9510924B publication Critical patent/ZA9510924B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9510924A 1994-12-22 1995-12-21 Soluble 2-chloro-2'-deoxyadenosine formulations ZA9510924B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36208394A 1994-12-22 1994-12-22

Publications (1)

Publication Number Publication Date
ZA9510924B true ZA9510924B (en) 1997-06-23

Family

ID=23424634

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9510924A ZA9510924B (en) 1994-12-22 1995-12-21 Soluble 2-chloro-2'-deoxyadenosine formulations

Country Status (15)

Country Link
US (1) US5681822A (de)
EP (1) EP0801571B1 (de)
JP (1) JPH10512549A (de)
AT (1) ATE223221T1 (de)
CA (1) CA2208484C (de)
CZ (1) CZ194297A3 (de)
DE (1) DE69528080T2 (de)
DK (1) DK0801571T3 (de)
ES (1) ES2182920T3 (de)
HU (1) HUT77928A (de)
IL (1) IL116469A0 (de)
PL (1) PL321431A1 (de)
PT (1) PT801571E (de)
WO (1) WO1996019230A1 (de)
ZA (1) ZA9510924B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US6194395B1 (en) * 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
DK1610822T4 (en) * 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
CA2526099C (en) * 2003-06-20 2013-02-05 Ares Trading Sa Freeze-dried fsh / lh formulations
FR2873695A1 (fr) * 2004-07-30 2006-02-03 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un antibiotique ou un inhibiteur de resistance), leur synthese et leurs utilisations en tant qu'agent antibacterien
SG160391A1 (en) 2004-12-22 2010-04-29 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
US9925151B2 (en) 2006-05-24 2018-03-27 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
EP2343074A1 (de) 2009-12-23 2011-07-13 Merck Serono S.A. Verwendung von Purinanaloga zur Behandlung von Atemwegserkrankungen
BR112020010282A2 (pt) 2017-11-24 2020-11-17 Merck Patent Gmbh regime de cladribina para uso no tratamento de formas progressivas de esclerose múltipla
JP2023541877A (ja) 2020-09-10 2023-10-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫障害の処置のための新規の処置レジメン
EP4302091A1 (de) 2021-03-03 2024-01-10 Ares Trading S.A. Verbesserte behandlungsverfahren mit dmds zur behandlung von autoimmunerkrankungen und biomarker zur vorhersage und/oder optimierung dieser behandlungsverfahren

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4719295A (en) * 1985-12-31 1988-01-12 Warner-Lambert Company Compound 2-iodo-2'-deoxyadenosine
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4908441A (en) * 1988-07-19 1990-03-13 Warner-Lambert Company Deoxyadenosine compounds and methods of making and using the same
US5208327A (en) * 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
WO1993023058A1 (en) * 1992-05-19 1993-11-25 The Scripps Research Institute Use of 2-halo adenine derivatives as therapeutic agents against chronic myelogenous leukemia

Also Published As

Publication number Publication date
CZ194297A3 (en) 1997-10-15
JPH10512549A (ja) 1998-12-02
DK0801571T3 (da) 2003-01-06
EP0801571B1 (de) 2002-09-04
PT801571E (pt) 2002-12-31
DE69528080T2 (de) 2003-06-05
DE69528080D1 (de) 2002-10-10
WO1996019230A1 (en) 1996-06-27
ES2182920T3 (es) 2003-03-16
ATE223221T1 (de) 2002-09-15
IL116469A0 (en) 1996-03-31
EP0801571A1 (de) 1997-10-22
HUT77928A (hu) 1998-11-30
CA2208484A1 (en) 1996-06-27
CA2208484C (en) 2008-09-23
PL321431A1 (en) 1997-12-08
US5681822A (en) 1997-10-28

Similar Documents

Publication Publication Date Title
ZA9510865B (en) Stable 2-chloro-2'-deoxyadenosine formulations
PL300194A1 (en) Interferon conjugate, method of obtaining same and pharmaceutical composition containing it
EP0841936A4 (de) Konjugationsstabilisierte therapeutische agenz-zusammensetzungen, formulierungen zur zugabe und diagnostik
CA2151774A1 (en) Skin Disinfecting Formulations
MY121360A (en) Clear cleansing detergent systems.
MY131095A (en) Polyethylene protein conjugates.
CA2338754A1 (en) Cosmetic composition
WO1996017626A3 (en) Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
PH31626A (en) Aqueous risperidone formulations.
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
ZA976777B (en) Anthelmintic formulations.
BR9713866A (pt) Composição farmacéutica
ZA9510924B (en) Soluble 2-chloro-2'-deoxyadenosine formulations
MX203624B (es) Composiciones cosmeticas para el autobronceado de la piel, a base de dihidroxiacetona, alquilpoliglucosidos y alcoholes grasos.
PT932397E (pt) Formulacoes em aerossol medicinais compreendendo budesonida
TR199600499A2 (tr) S(+)-Etodolak'in oral formülasyonlari.
ZA978352B (en) Injection formulations of avermectins and milbemycins.
MX9700244A (es) Utilizacion de un poliholosido en una composicion limpiadora o desmaquillante, y composicion que lo incluye.
ZA949874B (en) B3-adrenergic agents, benzodioxole dicarboxylates and their use in pharmaceutical compositions.
ZA962461B (en) Low dose ridogrel formulations.
JO1907B1 (en) Dissolved compounds of 2-chloro-2-dioxin adenosine
JO1908B1 (en) Static compounds of 2-chloro-2-dioxin adenosine
HK1007867A1 (en) Gel cleanser composition.
CA2208241A1 (en) Stable solutions of 2-chloro-2'-deoxyadenosine formulations
ZA97902B (en) Biologically active ureido derivatives useful in the treatment of multiple sclerosis.